Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques

Neutralizing antibodies are thought to be crucial for HIV vaccine protection, but studies in animal models suggest that high antibody concentrations are required. This is a major potential hurdle for vaccine design. However, these studies typically apply a large virus inoculum to ensure infection in control animals in single-challenge experiments. In contrast, most human infection via sexual encounter probably involves repeated exposures to much lower doses of virus. Therefore, animal studies may have provided an overestimate of the levels of antibodies required for protection in humans. We investigated whether plasma concentrations of antibody corresponding to relatively modest neutralization titers in vitro could protect macaques from repeated intravaginal exposure to low doses of a simian immunodeficiency virus–HIV chimera (SHIV) that uses the CC chemokine receptor 5 (CCR5) co-receptor. An effector function–deficient variant of the neutralizing antibody was also included. The results show that a substantially larger number of challenges is required to infect macaques treated with neutralizing antibody than control antibody–treated macaques, and support the notion that effector function may contribute to antibody protection. Overall, the results imply that lower amounts of antibody than previously considered protective may provide benefit in the context of typical human exposure to HIV-1.

[1]  C. Kim,et al.  Repetitive exposures with simian/human immunodeficiency viruses: strategy to study HIV pre‐clinical interventions in non‐human primates , 2006, Journal of medical primatology.

[2]  P. Sen,et al.  Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model , 2001, AIDS.

[3]  John R. Mascola,et al.  Analysis of Neutralization Specificities in Polyclonal Sera Derived from Human Immunodeficiency Virus Type 1-Infected Individuals , 2008, Journal of Virology.

[4]  Tahir A. Rizvi,et al.  Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection , 2000, Nature Medicine.

[5]  I. Longini,et al.  Preclinical Assessment of HIV Vaccines and Microbicides by Repeated Low-Dose Virus Challenges , 2005, PLoS medicine.

[6]  J. Mascola,et al.  Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies , 1999, Journal of Virology.

[7]  Mark Connors,et al.  Broad HIV-1 neutralization mediated by CD4-binding site antibodies , 2007, Nature Medicine.

[8]  John R Mascola,et al.  Defining the protective antibody response for HIV-1. , 2003, Current molecular medicine.

[9]  D R Burton,et al.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. , 1994, Science.

[10]  R. Royce,et al.  Sexual transmission of HIV. , 1997, The New England journal of medicine.

[11]  L. Grohskopf,et al.  Multiple vaginal exposures to low doses of R5 simian-human immunodeficiency virus: strategy to study HIV preclinical interventions in nonhuman primates. , 2005, The Journal of infectious diseases.

[12]  D. Burton,et al.  Fc receptor but not complement binding is important in antibody protection against HIV , 2007, Nature.

[13]  Tongqing Zhou,et al.  Structural definition of a conserved neutralization epitope on HIV-1 gp120 , 2007, Nature.

[14]  J. Mascola,et al.  Frequency and Phenotype of Human Immunodeficiency Virus Envelope-Specific B Cells from Patients with Broadly Cross-Neutralizing Antibodies , 2008, Journal of Virology.

[15]  C. Cheng‐Mayer,et al.  Mucosal Transmission and Induction of Simian AIDS by CCR5-Specific Simian/Human Immunodeficiency Virus SHIVSF162P3 , 2001, Journal of Virology.

[16]  M. Carrington,et al.  The High-Frequency Major Histocompatibility Complex Class I Allele Mamu-B*17 Is Associated with Control of Simian Immunodeficiency Virus SIVmac239 Replication , 2006, Journal of Virology.

[17]  C. Barbas,et al.  Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1 , 1997, Nature Medicine.

[18]  D. Richman,et al.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  D. Watkins,et al.  Molecular typing of major histocompatibility complex class I alleles in the Indian rhesus macaque which restrict SIV CD8+ T cell epitopes , 2007, Immunogenetics.

[20]  C. Cheng‐Mayer,et al.  In vivo adaptation of SHIVSF162: Chimeric virus expressing a NSI, CCR5‐specific envelope protein , 1999, Journal of medical primatology.

[21]  N. Haigwood,et al.  Determination of a Statistically Valid Neutralization Titer in Plasma That Confers Protection against Simian-Human Immunodeficiency Virus Challenge following Passive Transfer of High-Titered Neutralizing Antibodies , 2002, Journal of Virology.

[22]  C. Cheng‐Mayer,et al.  Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro , 2001, Journal of Virology.

[23]  Xuesong Yu,et al.  Factors Associated with the Development of Cross-Reactive Neutralizing Antibodies during Human Immunodeficiency Virus Type 1 Infection , 2008, Journal of Virology.

[24]  Renate Kunert,et al.  Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies , 2004, Journal of Virology.

[25]  P. Parren,et al.  Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1 , 2001, Journal of Virology.

[26]  Douglas D. Richman,et al.  Dissecting the Neutralizing Antibody Specificities of Broadly Neutralizing Sera from Human Immunodeficiency Virus Type 1-Infected Donors , 2007, Journal of Virology.

[27]  J. Lifson,et al.  Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS , 2005, Journal of medical primatology.

[28]  D. Watkins,et al.  Subdominant CD8+ T-Cell Responses Are Involved in Durable Control of AIDS Virus Replication , 2007, Journal of Virology.

[29]  N. Haigwood,et al.  Neutralizing antibody directed against the HIV–1 envelope glycoprotein can completely block HIV–1/SIV chimeric virus infections of macaque monkeys , 1999, Nature Medicine.

[30]  John P. Moore,et al.  Which Topical Microbicides for Blocking HIV-1 Transmission Will Work in the Real World? , 2006, PLoS medicine.

[31]  Christopher D Pilcher,et al.  Brief but efficient: acute HIV infection and the sexual transmission of HIV. , 2004, The Journal of infectious diseases.

[32]  O. Laeyendecker,et al.  Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. , 2005, The Journal of infectious diseases.

[33]  R. Doms,et al.  Dissecting the neutralizing antibody specificities of broadly neutralizing sera from 1 HIV-1 infected donors 2 * , 2007 .

[34]  J. Mascola,et al.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies , 2000, Nature Medicine.

[35]  Christophe Fraser,et al.  HIV-1 transmission, by stage of infection. , 2008, The Journal of infectious diseases.

[36]  Michael Monsour,et al.  Direct stringency comparison of two macaque models (single‐high vs. repeat‐low) for mucosal HIV transmission using an identical anti‐HIV chemoprophylaxis intervention , 2007, Journal of medical primatology.